[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341125-105":59,"doc-detail-341125-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","interleukin-15-armored-gpc3-car-t-cells-for-patients-with-solid-cancers","Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","","Interleukin-15 (IL15) enhances T-lymphocyte survival and improves the antitumor activity of CAR T cells in preclinical models of solid tumors where CAR T efficacy is limited. Glypican-3 (GPC3) is expressed across multiple solid cancer types, and this work evaluates IL15 co-expression effects on GPC3-CAR T cells in humans. Cohort 1 showed safety without objective responses, while Cohort 2 with IL15 co-expression demonstrated increased expansion, a 66% disease control rate, 33% antitumor response, and cytokine release syndrome managed by a safety switch.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/interleukin-15-armored-gpc3-car-t-cells-for-patients-with-solid-cancers/341125/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/interleukin-15-armored-gpc3-car-t-cells-for-patients-with-solid-cancers/341125.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does IL15 play in GPC3-CAR T cell therapy?","Question",{"text":112,"@type":113},"IL15 promotes T-lymphocyte survival and enhances the antitumor properties of CAR T cells. In this study, IL15 co-expression was tested to improve GPC3-CAR T cell performance in patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the two patient cohorts differ in outcomes?",{"text":117,"@type":113},"Cohort 1 received GPC3-CAR T cells and was safe but produced no objective antitumor responses, with peak expansion at two weeks. Cohort 2 received GPC3-CAR T cells co-expressing IL15 and showed significantly increased cell expansion, with a 66% disease control rate and 33% antitumor response rate.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety management strategy was used when cytokine release syndrome increased?",{"text":121,"@type":113},"In cohort 2, infusion of IL15-co-expressing CAR T cells was associated with increased cytokine release syndrome. The syndrome was rapidly ameliorated by activating an inducible caspase 9 safety switch.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341125,1790217738,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Baylor College of Medicine [https://orcid.org/0000-0002-4263-9115](https://orcid.org/0000-0002-4263-9115)  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine [https://orcid.org/0000-0003-1957-7160](https://orcid.org/0000-0003-1957-7160)  \nBaylor College of Medicine  \nBaylor College of Medicine  \nUniversity of Pennsylvania and Children's Hospital of Philadelphia [https://orcid.org/0000-0002-8088-](https://orcid.org/0000-0002-8088-)[ ](https://orcid.org/0000-0002-8088-)7929  \nChildren's Hospital of Philadelphia  \nUniversity of Pennsylvania  \nUniversity of Houston [https://orcid.org/0000-0001-7524-8228](https://orcid.org/0000-0001-7524-8228)  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nBaylor College of Medicine  \nUniversity of North Carolina  \nBaylor College of Medicine  \nBaylor College of Medicine [https://orcid.org/0000-0001-7049-7698](https://orcid.org/0000-0001-7049-7698)  \nBaylor College of Medicine  \nBaylor College of Medicine  \nApril 3rd, 2024  \n [https://doi.org/10.21203/rs.3.rs-4103623/v1](https://doi.org/10.21203/rs.3.rs-4103623/v1)  \n 􀁱 􀅏 This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License  \n there is potential Competing Interest. The corresponding author (AH) has patents related to GPC3-CARs. AH is consultant for Waypoint Bio and serves on the Scienti¦c Advisory Board of CARGO Therapeutics. AH has equity in CARGO. AH received research support from  \nKuur/Athenex Therapeutics.  \n1 Title: Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers 2  \n3 Authors: David Steffin1-4, Nisha Ghatwai 1,2, Antonino Montalbano 1,2, Purva Rathi 1,2, Amy N Courtney 1-3, 4 Azlann B Arnett2,5, Julien Fleurence 1,3, Ramy Sweidan5, Thao Wang3, Huimin Zhang5 , Prakash Masand6, John 5 M Maris7, Daniel Martinez8, Jennifer Pogoriler8, Navin Varadarajan9, Sachin G Thakkar5, Deborah Lyon5, 6 Natasha Lapteva5,10,11, Zhuyong Mei5, Kalyani Patel 11, Dolores Lopez-Terrada 11, Carlos Ramos3, 5, Premal  \n7 Lulla3, 5, Tannaz Armaghany3, Bambi J Grilley 1-4, Gianpietro Dotti 12, Leonid S Metelitsa 1-3,5, Helen E Heslop3,5, 8 Malcolm K Brenner3,5, Pavel Sumazin 1,3, Andras Heczey 1-3,13 *  \n9  \n10 Affiliations:  \n11 1Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.  \n12 2Center for Advanced Innate Cell Therapy, Baylor College of Medicine, Houston, Texas.  \n13 3Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.  \n14 4 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.  \n15 5 Department of Immunology and Microbiology, Baylor College of Medicine, Texas.  \n16 6Department of Radiology, Baylor College of Medicine, Houston, Texas.  \n17 7Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the  \n18 University of Pennsylvania, Philadelphia, Pennsylvania.  \n19 8Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at  \n20 the University of Pennsylvania, Philadelphia, Pennsylvania.  \n21 9William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston,  \n22 Houston, Texas.  \n23 10Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.  \n24 11Department of Pathology, Baylor College of Medicine, Houston, Texas.  \n25 12Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.  \n26 13Texas Children's Hospital Liver Tumor Program, Houston, Texas.  \n27  \n28 *[Corresponding autho","cbCaihbiTaGjjmec","https://ap.wps.com/l/cbCaihbiTaGjjmec","pdf",1034442,22,"English","# Summary paragraph\n# Introduction","[{\"question\":\"What role does IL15 play in GPC3-CAR T cell therapy?\",\"answer\":\"IL15 promotes T-lymphocyte survival and enhances the antitumor properties of CAR T cells. In this study, IL15 co-expression was tested to improve GPC3-CAR T cell performance in patients.\"},{\"question\":\"How did the two patient cohorts differ in outcomes?\",\"answer\":\"Cohort 1 received GPC3-CAR T cells and was safe but produced no objective antitumor responses, with peak expansion at two weeks. Cohort 2 received GPC3-CAR T cells co-expressing IL15 and showed significantly increased cell expansion, with a 66% disease control rate and 33% antitumor response rate.\"},{\"question\":\"What safety management strategy was used when cytokine release syndrome increased?\",\"answer\":\"In cohort 2, infusion of IL15-co-expressing CAR T cells was associated with increased cytokine release syndrome. The syndrome was rapidly ameliorated by activating an inducible caspase 9 safety switch.\"}]","Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers | PDF",1790040433,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/690cd1235ce11917e00f8c4442a08a53.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bd9982f170e651366702f8aa9ee9be7.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d4bc659cf7361c552393b957464d0f2.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d53d24ed20e80e114881ef290f859404.webp",980,1268]